Fluvoxamine for treatment of psoriasis

EP4469032A1Pending Publication Date: 2024-12-04FACULDADE DE FARMACIA DA UNIV DE LISBOA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
EP2023703903
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-01-28
Filing Date
2023-01-27
Publication Date
2024-12-04

AI Technical Summary

Technical Problem

Current treatments for psoriasis often require long-term systemic administration, which can be burdensome and may not effectively address dermatological symptoms, necessitating an alternative administration route with better efficacy.

Method used

A topical formulation of fluvoxamine as an oil-in-water emulsion, with a drug dose range of 25 mg/g to 50 mg/g, specifically formulated to provide effective anti-inflammatory action directly on skin lesions, reducing the need for systemic treatments.

Benefits of technology

The topical fluvoxamine formulation demonstrates significant anti-inflammatory effects in psoriasis models, achieving symptom relief with lower doses compared to oral administration, effectively addressing the inflammatory processes in psoriasis with improved patient adherence and quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000019_0001
    Figure IMGF000019_0001
  • Figure 00000032_0000
    Figure 00000032_0000
  • Figure 00000032_0001
    Figure 00000032_0001
Patent Text Reader

Abstract

The present invention relates to fluvoxamine for use in the treatment of psoriasis as a topical formulation.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] DESCRIPTION

[0002] "FLUVOXAMINE FOR TREATMENT OF PSORIASIS"

[0003] FIELD OF THE INVENTION

[0004] The present invention relates to fluvoxamine for use in the treatment of psoriasis as a topical formulation .

[0005] BACKGROUND OF THE INVENTION

[0006] Psoriasis is a chronic immune-mediated skin disease , with a pathogenesis resulting from a combination of genetic and environmental factors . The pathogenesis of psoriasi s is driven by the interaction between innate and adaptive immune cells and keratinocytes , in a complex process mediated by cytokines and other signaling molecules . This leads to an inflammatory process with increased proli feration of epidermal cells , neoangiogenesis , and infiltration of white cells in the skin, which cause the characteristic psoriasis plaques .

[0007] Several studies as described for example in Martins , Ana M . , "The Brain-Skin Connection and the Pathogenesis of Psoriasis : A Review with a Focus on the Serotonergic System" , Cells 2020 , 9 , 796 , have suggested that the neurotransmitter serotonin, a key mediator between the skin and the neuroendocrine system, also plays an important role in the pathogenesis of psoriasis . Also , the cytokine theory of depression suggests that depression and other mental disorders have hormonal and biochemical components and might involve inflammation processes . For the treatment of depression and anxiety disorder, SSRI s are orally administered at the following dosage ranges :

[0008] Fluoxetine - 20 to 60 mg / daily

[0009] Paroxetine - 20 to 50 mg / daily

[0010] Escitalopram - 10 to 20 mg / daily

[0011] Fluvoxamine - 50 to 300 mg / daily

[0012] Sertraline - 25 to 200 mg / daily

[0013] Further, said drugs used to treat depression as aforementioned have also been shown to have anti-inflammatory and antioxidant ef fects , additionally to their antidepressant action . These drugs perform an indirect role in psoriasis as they act systematically as antidepressants , but they can have a positive ef fect on the dermatological symptoms of psoriasis .

[0014] Thorslund et al . , "Use of serotonin reuptake inhibitors in patients with psoriasis is associated with a decreased need for systemic psoriasis treatment : a population-based cohort study" , Journal of Internal Medicine , Volume 274 , I ssue 3 , September 2013 , performed a population-based cohort study to investigate whether psoriasis was af fected by the oral administration of SSRI s , namely fluoxetine , paroxetine , citalopram, escitalopram, fluvoxamine , and sertraline . The study, where fluvoxamine was used at a 40 to 90% of a 100 mg per day ( 40 to 90 mg per day) , showed that the treatment of mild psoriasis patients with SSRI s reduced the need for systemic psoriasis treatment . However, this kind of action and attenuation of psoriasis was only revealed for antidepressants that are orally administrated . Psoriasis often needs long-term treatment , which can be a burden . Thus , the choice of the treatment is crucial to increase the patients ' adherence and quality of li fe .

[0015] Thus , there is still the need to provide an alternative treatment of psoriasis that provides an easy and ef fective administration route together with a better treatment ef ficacy .

[0016] SUMMARY OF THE INVENTION

[0017] Surprisingly, the aforementioned problem was solved by the present invention .

[0018] The present invention provides fluvoxamine for use in the treatment of psoriasis as a topical formulation .

[0019] In one embodiment , fluvoxamine as a topical formulation has a drug dose in a range from 25 mg / g to 50 mg / g, preferably in a range from 20 mg / g to 30 mg / g and more preferably the topical formulation has a drug dose of 25 mg / g .

[0020] In another embodiment , fluvoxamine as a topical formulation is an oil-in-water emulsion .

[0021] BRIEF DESCRIPTION OF DRAWINGS

[0022] Figure 1 shows the in vitro anti-inflammatory ef fect of the initial studied SSRI s ( sertraline hydrochloride , fluoxetine hydrochloride , fluvoxamine maleate , paroxetine hydrochloride and escitalopram oxalate) on the reduction of the expression of pro- inflammatory cytokines by differentiated THP-1 cells. The graph shows the concentrations of each SSRI solution which can reduce the concentration of produced cytokines (IL-lp and TNF-a) by 50%. Results are mean ± standard deviation, n=6.

[0023] Figure 2 shows the anti-inflammatory effect of fluvoxamine maleate and escitalopram oxalate gels on a Croton-oil model of atopic dermatitis (inflammation model) in mice. The control is the placebo, i.e., the vehicle of the API formulations. Results are mean ± standard deviation, n=3.

[0024] Figure 3 shows the anti-inflammatory effect of fluvoxamine maleate and escitalopram oxalate gels on an imiquimod-induced model of psoriasis (inflammation model) in mice. The first graph shows the legend for all the graphs. The negative control is the placebo, i.e., the vehicle of the drug formulations, while the positive control is Dermovate, an anti-inflammatory drug. The graphs show the PAST scores obtained. Results are mean ± standard deviation, n=6. (A) Erythema; (B) Scaling; (C) Thickness; (D) Cumulative.

[0025] Figure 4 shows the histological images of mice skin obtained from the in vivo studies of the anti-inflammatory effect of fluvoxamine and escitalopram on an IMQ-induced model of psoriasis of Figure 3. Measurements were performed in slides digitally scanned in the NanoZoomerSQ with NDP.view2 software (Hamamatsu, Japan) corresponding to the mean value obtained from 7 to 12 different points for epidermis and dermis layers. The placebo (vehicle of the drug formulations) is the negative control while Dermovate is the positive control (antiinflammatory) . (A) Normal skin: No changes (HE; 8x magnification) ; (B) Skin treated with placebo: Epidermal hyperplasia, diffuse, moderate; orthokeratotic hyperkeratosis, diffuse, mild (HE; 8x magnification) ; (C) Skin treated with Dermovate: Epidermal hyperplasia, diffuse, mild; orthokeratotic hyperkeratosis, diffuse, mild (HE; 8x magnification) ; (D) Skin treated with Fluvoxamine : Epidermal hyperplasia, diffuse, moderate; orthokeratotic hyperkeratosis, diffuse, mild (HE; 8x magnification) ; (E) Skin treated with Escitalopram: Epidermal hyperplasia, diffuse, moderate; orthokeratotic and parakeratotic hyperkeratosis, diffuse, mild (HE; 8x magnification) ; (F) Skin treated with Escitalopram: Focal area of extensive epidermal erosion covered by serocelular fibrinous crust with necrotic derbis and neutrophils, moderate (HE; lOx magnification) .

[0026] Figure 5 shows the results of viscosity tests (rheological analysis) for the final emulsions with different concentrations of fluvoxamine maleate (compositions shown in Table 4) . (A)

[0027] Table of shear stress; (B) Yield stress ramp test; (C) Ramp up / ramp down test.

[0028] Figure 6 shows the results of the oscillatory tests (rheological analysis) for the final emulsions with different concentrations of fluvoxamine maleate (compositions shown in Table 4) . (A) Strain amplitude sweep test; (B) Frequency sweep test; (C) Tan (5) vs. frequency.

[0029] Figure 7 shows the droplet size distribution profile for the final emulsions with different concentrations of fluvoxamine maleate and placebo (composition shown in Table 4) .

[0030] Figure 8 shows the optical microscopy images of the final emulsions (F1-F5) with different concentrations of fluvoxamine maleate (composition shown in Table 4) and placebo obtained with 40x magnification, under non-polarized light.

[0031] Figure 9 shows the anti-inflammatory effect of the emulsions with different concentrations of fluvoxamine (composition shown in Table 4) on an imiquimod-induced model of psoriasis in mice. The graph shows the PAST cumulative scores (erythema + scaling + thickness) for the different samples. Placebo (vehicle of the drug formulations) is the negative control while Dermovate is the positive control (antiinflammatory) . Results are mean ± standard deviation, n=6.

[0032] Figure 10 shows the histological images of mice skin obtained from the in vivo studies of the anti-inflammatory effect of the different fluvoxamine emulsions (5 mg / g, 25 mg / g and 50 mg / g) and on an IMQ-induced model of psoriasis. Measurements were performed in slides digitally scanned in the NanoZoomerSQ with NDP.view2 software (Hamamatsu, Japan) corresponding to the mean value obtained from 7 to 12 different points for epidermis and dermis layers. The placebo (vehicle of the drug formulations) is the negative control while Dermovate is the positive control (anti-inflammatory) . The composition of the emulsions is shown in Table 4. (A) Normal skin: No changes (HE; 5x magnification) ; (B) Skin treated with placebo: Epidermal hyperplasia, diffuse, marked; orthokeratotic hyperkeratosis, diffuse, mild; with occasional erosions covered by serofibrinous crust, and lymphoplasmocytic inflammatory cell infiltration, moderate (HE; 5x magnification) ; (C) Skin treated with Dermovate: Epidermal hyperplasia, diffuse, minimal; orthokeratotic hyperkeratosis, diffuse, minimal (HE; 5x magnification) ; (D) Skin treated with 5 mg / g Fluvoxamine emulsion: Epidermal hyperplasia, diffuse, marked; orthokeratotic hyperkeratosis, diffuse, mild; and lymphoplasmocytic inflammatory cell infiltration, mild (HE; 5x magnification) ; (E) Skin treated with 25 mg / g Fluvoxamine emulsion: Epidermal hyperplasia, diffuse, moderate; orthokeratotic and parakeratotic (nuclear retention) hyperkeratosis, diffuse, moderate; with occasional erosions covered by serofibrinous crust and lymphoplasmocytic inflammatory cell infiltration, moderate (HE; 5x magnification) ; (F) Skin treated with 50 mg / g Fluvoxamine emulsion: Epidermal hyperplasia, diffuse, moderate; orthokeratotic and parakeratotic (nuclear retention) hyperkeratosis, diffuse, moderate; with occasional erosions covered by serofibrinous crust and lymphoplasmocytic inflammatory cell infiltration, mild (HE; 5x magnification) ;

[0033] Figure 11 shows the in vitro release profile of fluvoxamine from the emulsions (2.5% w / w = 25 mg / g and 5% w / w = 50 mg / g) and a solution, for comparison. The results were obtained in in vitro studies using Franz cells, Results are average ± standard deviation, n =6.

[0034] DETAILED DESCRIPTION OF THE INVENTION

[0035] To solve the problems identified above, the present invention provides fluvoxamine for use in the treatment of psoriasis as a topical formulation.

[0036] In the context of the invention, an emulsion is a heterogeneous system composed of two immiscible liquids, in which one of the liquids is evenly dispersed in the other in the form of fine droplets. Further, the emulsions of the present invention are oil in water (O / W) emulsions. Within the meaning of the present invention, fluvoxamine includes any pharmaceutically acceptable salts , esters or solvates thereof . In particular, fluvoxamine maleate is preferred .

[0037] Drug dose in the context of the present invention i s meant as the quantity (mg) of the drug per g of formulation . In particular, drug dose is meant as the amount of fluvoxamine , in mg, present in 1 g of the formulation prepared as described in the examples hereinbelow .

[0038] The percentages as indicated refers to weight / weight percentages unless otherwise speci fied .

[0039] In the context of the present invention, the amount of fluvoxamine may be referred in percentage weight / weight or in mg / g . For easy reference , 5% w / w of fluvoxamine corresponds to 50 mg / g .

[0040] In the present invention, a topical formulation or vehicle is defined as the substance that carries a specific drug ( active ingredient ) , in particular fluvoxamine , into contact with and through the skin .

[0041] In the context of the invention, room temperature means a temperature in the range of 20 to 30 ° C±2 ° C .

[0042] Surprisingly, fluvoxamine which is an anti-depressive acting in the central nervous system ( CNS ) was found to act as a local anti-inflammatory in skin lesions when formulated as a topical emulsion . In particular, fluvoxamine has revealed to be an ef fective drug for topical administration in the treatment of psoriasis , which causes a local skin inflammatory process and thus fluvoxamine can treat this disease and, in more severe cases , can relieve the symptoms caused by the disease .

[0043] Further, fluvoxamine as topical formulation has also surprisingly revealed to be more ef fective with a lower drug dose when compared to fluvoxamine orally administered . The present invention shows that a lower concentration of a fluvoxamine emulsion in a range from 25 mg / g to 50 mg / g, namely 25 mg / g, alleviated the inflammatory symptoms of psoriasis in vi vo, in an IMQ-induced psoriasis model in mice ( as it will be described in detail hereinbelow) . Due to the skin barrier ef fect , especially due to the stratum corneum ( SC ) , this result is fully unexpected .

[0044] The main barrier to the percutaneous absorption of topically applied drugs is the SC . The structure of the SC can be described by a multilayer matrix of hydrophobic and hydrophilic components , which form a barrier to penetration of irritants , allergens , and pathogenic microorganisms through skin . The structural integrity of the SC is maintained by the presence of modi fied desmosomes , called corneodesmosomes , which lock the corneocytes together and provide tensile strength for the SC to resist to shearing forces .

[0045] The barrier nature of the SC depends critically on its unique constituents ; unlike the typical biological membranes mainly composed by phospholipids , the hydrophobic l ipids present in the intercellular spaces of the SC are ceramides ( 45-50% consist of a sphingosine or a pt / tosphingosine base to which a non-hydroxy fatty acid or an alpha-hydroxy fatty acid is chemically linked) , cholesterol (250 mg / g) , long-chain free fatty acids mostly with chain lengths C22 and C24 (150 mg / g, highly enriched in linoleic acid) , and 50 mg / g other lipids, the most important being cholesterol sulphate, cholesterol esters, and glucosylceramides (Pivetta, T.P. et al., "Development of nanoparticles from natural lipids for topical delivery of thymol: Investigation of its anti-inflammatory properties", Colloids Surf B Biointerfaces, 164 (2018) 281-290) . These lipids, which are organized in multilamellar bilayers, regulate the passive flux of water through the SC and are considered very important for skin barrier function.

[0046] It is known in the art that drugs must be administered at higher concentrations topically than systematically, to obtain similar effects, and the present invention contradicts this fact and surprisingly allows a better treatment efficacy with a lower drug dose.

[0047] In one embodiment, fluvoxamine as a topical formulation has a drug dose in a range from 25 mg / g to 50 mg / g, preferably in a range from 20 mg / g to 30 mg / g. In a preferred embodiment, the topical formulation has a drug dose of 25 mg / g.

[0048] Semisolid formulations, such as creams, gels and lotions, are the preferred pharmaceutical vehicles for topical therapy due to the fact that they remain in situ and usually provide an extended drug release.

[0049] EXAMPLES

[0050] The present invention is described in more detail and specifically with reference to the examples, which are not intended to be limitative.

[0051] 1. Pre-formulation studies

[0052] 1.1. Initial formulations development

[0053] The pre-formulation process consisted of solubility studies, choice of emulsifiers, thickening agents and oil phase and the preparation and characterization of the initial formulations .

[0054] 1.1.1. Solubility studies

[0055] Several pre-formulation emulsion solvents were used in solubility tests of the Active Pharmaceutical Ingredients (from now on APIs) which are 5 selective serotonin reuptake inhibitors (from now on SSRIs) . The pre-formulation emulsion solvents were as follows: Emosmart™ C28, Emosmart™ V21, Tegosoft® CT, water; other possible solvents were Tegosoft® TN, Tegosoft® APM, Tegosoft® TIS, Tegosoft® XC, Massocare IPI, Isopropyl myristate, Cegesoft® C24, Transcutol® P.

[0056] The best results were obtained with Transcutol® P, which was used as a humectant and incorporated in all test emulsions. 1.1.2. Choice of other components

[0057] The other components of the formulation, such as emulsifiers, thickening agents and the oil phase, were chosen from those mentioned herein below:

[0058] (i) Scanning of different emulsifiers (at a 3% concentration) to create O / W emulsions: Abil® Care XL 80, Abil® Care 85, Tego® Care LTP, Tego® Wipe Lux, Fluidifeel™ Easy.

[0059] (ii) Testing acrylated thickening agents (two different concentrations, 1.5% and 2%) : Sepinov® EMT 10 and Sepiplus® 400.

[0060] (iii) The oil phase was composed by Emosmart™ V21, Emosmart™

[0061] C28, and Tegosoft® CT. The pre-formulation studies included increase of the oil phase from 9% to 15%.

[0062] The pre-formulation tests led to 23 different formulations

[0063] (without API ) .

[0064] 1.1.3. Preparation and characterization of the emulsions

[0065] Oil in water (0 / W) emulsions were prepared by a cold process, performed at room temperatures as disclosed in Cox, R., "Cold processing of emulsions", Cosmet. Toliletries, 2013, pp . 1-8. The process consisted in the separate preparation of an aqueous and an oil phase. After the two phases were manually homogenized, they were emulsified at room temperature with high shear mixing at a rate of about 10000 rpm / min (IKA T25 Ultra Turrax) for about 1 minute. The formulations developed were tested for: (i) pH, (ii) macroscopic organoleptic analysis (viscosity and phases separation) , (iii) physical stability (centrifugation) test, (iv) type of emulsion, (v) physical characterization (droplet size analysis, microscopic analysis, and rheological studies) . A validation / exclusion method was applied .

[0066] 1.2. Choice of preservatives

[0067] Five different preservatives were tested, namely: Geogard Ultra® (1.5%) , Benzyl alcohol (1%) , Nipagin™ M Sodium (0.18%) and Nipasol M Sodium™ (0.02%) , Dermosoft® OMP (3%) , and SymCalmin® (2%) . The selection of the preservative was based on accelerated physical stability, droplet size, microscope aspect of the emulsion, and rheological characteristics. The addition of preservatives required the additional addition of a thickening agent, Lecigel™.

[0068] The results obtained led to the choice of the combination Nipagin™ M Sodium (0.18%) and Nipasol M Sodium™ (0.02%) as the preservative .

[0069] 1.3. Composition of the final formulation

[0070] After preparing and testing the 23 emulsions as described previously, a final formulation was chosen with a composition described in Table 1. Table 1. Composition of the emulsion obtained in pre- formulation studies (formulation without API) .

[0071] COMPOSITION

[0072] CHEMICAL NAME % (w / w) FUNCTION

[0073] To 100 Aqueous

[0074] Purified water vehicle

[0075] Diethylene Glycol 5.0 Humectant

[0076] Monoethyl Ether

[0077] Sodium Acrylates 1.0

[0078] Copolymer, Lecithin

[0079] Hydroxyethyl 2.0 Thickening

[0080] Acrylate / Sodium agent

[0081] Acryloyldimethyl

[0082] AQUEOUS

[0083] Taurate Copolymer

[0084] PHASE

[0085] Sodium Methylparaben 0.18

[0086] _ Preservatives

[0087] Sodium Propylparaben 0.02

[0088] Bis-PEG / PPG-20 / 5 3.0

[0089] PEG / PPG-20 / 5

[0090] Dimethicone, Methoxy

[0091] PEG / PPG-25 / 4 Emulsifier

[0092] Dimethicone,

[0093] Caprylic / Capric

[0094] Triglyceride

[0095] C18-C21 alkane 5.0

[0096] OIL C21-C28 alkane 5.0

[0097] Emollient

[0098] PHASE Caprylic / Capric 5.0

[0099] Triglycerides 2. Drug selection

[0100] 2.1. In vitro cytotoxicity and anti-inflammatory studies

[0101] The five SSRIs (sertraline, fluoxetine, paroxetine, escitalopram, fluvoxamine) were tested in vitro in the human keratinocyte HaCaT cell line (CLS, Germany) and in the human monocytic THP-1 cell line (ATCC TIB-202™) . THP-1, THP-l-derived macrophages (differentiation induced by 100 ng / mL E. coli LPS and 100 nM PMA for 24 h (as disclosed in Lund, M.E. et al. , "The choice of phorbol 12-myristate 13-acetate differentiation protocol influences the response of THP-1 macrophages to a pro- inflammatory stimulus", J Immunol Methods, 430 (2016) 64-70) , and HaCaT cells were exposed to medium containing different drug concentrations for 24 h.

[0102] Cytotoxicity was assessed using the resazurin assay, which quantifies metabolically active cells as disclosed in Nociari, M.M. et al. , "A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity", J Immunol Methods, 213 (1998) 157-167. Inhibitory concentrations (IC50) were calculated using the GraphPad Prism software v5.0. The IC50 results obtained for the different cells are shown in Table 2. Sertraline is the most cytotoxic drug, while fluvoxamine and escitalopram show low cytotoxicity. Table 2. Concentration of SSRIs that reduced the cell viability to 50% after 24 h of incubation. THP-1 und. - undifferentiated cells, THP-1 dif. - cells differentiated with 100 ng / mL LPS and 100 nM PMA. Results are meanlSD, n=6.

[0103] IC50 (pM)

[0104] Drug

[0105] HaCaT THP-1 und. THP-1 dif.

[0106] Sertraline 36+3 34+5 28+6

[0107] Fluoxetine 48+10 50+2 53+1

[0108] Fluvoxamine > 200 > 200 > 200

[0109] Paroxetine 48+8 28+6 31+2

[0110] Escitalopram > 200 > 200 > 200

[0111] The anti-inflammatory action was tested by cell differentiation assays and immunoassay determination of cytokines. THP-1 monocytes were treated with different concentrations of each drug for 2 h prior to inducing their differentiation with LPS and PMA (24 h) . Supernatant aliquots were then retrieved and stored at -80 °C until cytokine determination. The non-adherent non-dif f erentiated cells were separated from the adherent differentiated ones and, in both cases, viable cells were quantified using the resazurin assay as described in Nociari, M.M. et al. (1998) . Untreated cells exposed to LPS and PMA were used as 100% differentiation controls, while unstimulated cells were used as blank controls. The pro-inflammatory cytokines IL1-0 and TNF-a were determined with the DuoSet Elisa Kits (R&D Systems) , according to the manufacturer's protocols. The determination of pro-inflammatory cytokines showed that fluvoxamine is the most effective drug in reducing the production of cytokines by differentiated THP-1 cells ( Figure 1 ) . The cytotoxicity and anti-inflammatory studies led to the choice of fluvoxamine and escitalopram as the promising SSRIs to proceed to further studies.

[0112] 2.2. In vivo studies - anti-inflammatory effect on an atopic dermatitis mice model

[0113] In vivo assays were performed in an atopic dermatitis (AD) model (Croton Oil Method) developed in NMRI mice, as described in Nociari, M.M. et al. (1998) . Gels of fluvoxamine and escitalopram were formulated with water, isopropyl alcohol and polymer, at adequate concentrations, applied to one of the mice ears (n=3 mice per formulation) and left to dry. One of the ears was left untreated and a group of mice (n=3) was treated with placebo (formulation without API) . After 16 h, the ear thickness was determined with a Mitutoya® micrometer as a measure of the edema .

[0114] The preliminary studies performed using the AD model showed high standard deviations and no significant differences between the two tested SSRIs, thus further in vivo studies were performed using a mice model of psoriasis.

[0115] 2.3. Solubility studies — addition of cyclodextrins

[0116] Solubility studies were necessary prior to incorporation of the drug in the formulation. Besides using Transcutol-P as the best solvent (section 1.1.1) , two cyclodextrins (di-methyl-p- cyclodextrin and y-cyclodextrin) were also tested for their capacity of complexation of the drugs, in a solution of purified water, 5% Transcutol® P and 50 mg / g drug.

[0117] Table 3. Minimum percentages of cyclodextrins (CyD) needed for the total solubilization of the SSRIs in water and 50 mg / g of Transcutol® P.

[0118] Es ci tai opram Fluvoxamine oxalate maleate

[0119] Di -methyl- >3% 12%

[0120] * CyD results are represented as "% of CyD in the total of the formulation"

[0121] The results of Table 3 showed that 12% of di-methyl-p-CyD were needed to fully solubilize fluvoxamine maleate, while escitalopram oxalate fully solubilized in the presence of 5% y- CyD. Thus, 12% di-methyl-p-CyD was chosen to be used in the formulations .

[0122] 2.4. In vivo studies - Anti-inflammatory and histology studies in IMQ-induced psoriasis developed in mice

[0123] In order to select the API for incorporation in the developed placebo formulation (Table 1) , in vivo antipsoriatic activity tests for the two SSRIs selected in the previous in vitro and in vivo tests (fluvoxamine and escitalopram) were performed using an Imiquimod ( IMQ) -induced psoriasis model (as described in Pivetta, T.P. et al. , "Development of nanoparticles from natural lipids for topical delivery of thymol: Investigation of its anti-inflammatory properties", Colloids Surf B Biointerfaces, 164 (2018) 281-290) .

[0124] This study used 36 female BALB / c mice aged 6 weeks (Charles River Laboratories, France) and all experiments were carried out in accordance with the animal welfare body of the Faculty of Pharmacy, University of Lisbon, approved by the competent national authority (Directorate-General for Food and Veterinary - DGAV) and in accordance with the EU Directive ( 2010 / 63 / EU) , Portuguese laws (DL 113 / 2013, 2880 / 2015, 260 / 2016 and 1 / 2019) and all relevant legislation. The animals were housed in individual polypropylene cages at room temperature (20-24 °C) , relative humidity (55 ± 5%) , light / dark cycle for 12 hours, and received a standard feed and water ad libitum. The 36 mice were randomly assigned to six different groups: Group 1 (n = 6) animals treated with 60 mg of Dermovate® (containing 0.5 mg / g clobetasol propionate) as a positive control of inflammation inhibition; Group 2 (n = 6) - animals treated with 60 mg of placebo gel; Group 3 (n = 6) - animals treated with 60 mg of fluvoxamine maleate 50 mg / g gel; Group 4 (n = 6) - animals treated with 60 mg of escitalopram oxalate 50 mg / g gel; Group 6 (n = 6) - naive group.

[0125] The composition of the gels was based on the formulation selected in the pre-formulation studies and solubility tests. First, 12% of di-methyl-p-CyD was solubilized in purified water, followed by the addition of 50 mg / g of the drug (fluvoxamine maleate, sertraline hydrochloride) under magnetic stirring. In the second step 0.18% methylparaben and 0.02% propylparaben were added together with 5% Transcutol® P. The HPMC polymer was added in the end and the mixture was stirred in the Ultra Turrax for about 4 minutes , until the gelled appearance was observed .

[0126] The study was carried out for 6 consecutive days , with the treatments applied every day . First , all mice were shaved on the dorsal area and kept in individual cages . The treatments were applied to the shaved area and, 5 hours post-treatment , 60 mg of Aldara® cream containing 50 mg / g IMQ was applied, to induce psoriasis . After the first day, all mice were visually examined daily, after the treatment , and skin thickness and weight were measured . The psoriasis-inflammation evaluation criteria were assessed according to the clinical PAS T score : erythema, scaling, and thickening were scored from 0 to 4 ( 0 : none ; 1 : slight ; 2 : moderate ; 3 : marked; 4 : very marked) . The results are summari zed in Figure 3 .

[0127] The animals were euthani zed on the sixth day and the back- skin tissue was fixed with a 10% formalin solution . Tissues were cut into 4 pm longitudinal sections and then embedded in paraf fin and stained with haematoxylin and eosin . The evaluation was performed by a pathologist blinded to experimental groups . Measurements were performed in slides digitally scanned in the NanoZoomerSQ with NDP . view2 software (Hamamatsu, Japan) corresponding to the mean value obtained from 7 to 12 di f ferent points for epidermis and dermis layers . The results are shown in Figure 4 .

[0128] The results provide evidence that the treatment with fluvoxamine maleate led to the improvement of the symptoms caused by the previous application of the IMQ, with the skin presenting milder symptoms and less structural changes in the epidermis compared to the other treatments . Furthermore , statistical analysis suggests that treatment with fluvoxamine maleate presents results closer to positive control than placebo . In summary, these results led to the choice of fluvoxamine maleate to proceed to further studies .

[0129] 3. Development and characterization of the drug-containing emulsions

[0130] 3. 1. Preparation and composition

[0131] After choosing fluvoxamine maleate to be incorporated in the placebo emul sions , the aqueous and oily phases were prepared separately, at room temperature , and subsequently were emulsi fied . However, the incorporation of the drug caused changes in the characteristics of the emulsion, namely a loss of structure and consistency, which turned the formulation liquid . Thus , it was necessary to optimi ze the preparation of the aqueous phase by adding the polymer HPMC, with a tested range of concentrations 0 . 75% to 2 % . The addition of HPMC gave consistency to the formulations developed, but their chemical stability remained low, with phase separation after each accelerated stability study ( 3 cycles of centri fugation at 5000 rpm, 5 min each, room temperature , performed 1 day after the preparation) . To prevent this , the addition of 2 % of a thickening agent and stabili zer, Sepineo™ P600 , was tested . The composition of the final formulations to be tested is shown in Table 4 . Each compound of the formulation plays a dif ferent and important functions which is def ined as follows : water, solvent ; di-methyl- p-cyclodextrin, complexation molecule ; Diethylene glycol monoethyl ether ( Transcutol P ) , humectant ; Hydroxypropyl methylcellulose (HPMC ) and Acrylamide / Sodium Acryloyldimethyl Taurate Copolymer / Isohexadecane & Polysorbate 80 (Sepineo P 600) , thickening agents; Bis-PEG / PPG-20 / 5 PEG / PPG-20 / 5 Dimethicone (and) Methoxy PEG / PPG-25 / 4 Dimethicone (and) Capric Triglyceride (Abil Care XL 80) , surfactant; Sodium methylparaben (Nipagin) and Sodium Propylparaben (Nipazol) , preservatives; C18-21 Alkane (Emosmart V21) , C21-28 Alkane (Emosmart C28) and Caprylic / Capric Triglycerides (Tegosoft CT) , emollients.

[0132] Table 4. Composition of drug-containing emulsions (F1-F5) and placebo.

[0133] COMPOSITION

[0134] CHEMICAL N ME QUANTITATIVE COMPOSITION (%, w / w)

[0135] Place Fl F2 F3 F4 F5 bo

[0136] Water (Aqua) to to to to to to

[0137] 100 100 100 100 100 100

[0138] Di-methyl-p- 12.0 12.0 12.0 4.0 12.0 0.5 cyclodextrin Fluvoxamine -- 5.0 2.5 2.5 0.5 0.5 maleate

[0139] Diethylene glycol 5.0 5.0 5.0 5.0 5.0 5.0 monoethyl ether

[0140] Hydroxypropyl 1.0 1.0 1.0 1.0 1.0 1.0 methyl cellulose

[0141] Acrylamide / Sodium Acryloyldimethyl 1.0 1.0 1.0 1.0 1.0 1.0

[0142] Taurate

[0143] AQUEOUS Copolymer / Isohexad

[0144] PHASEecane &

[0145] Polysorbate 80

[0146] Bis-PEG / PPG-20 / 5

[0147] PEG / PPG-20 / 5

[0148] Dimethicone (and) 3.0 3.0 3.0 3.0 3.0 3.0

[0149] Methoxy PEG / PPG-

[0150] 25 / 4

[0151] Dimethicone (and)

[0152] Capric

[0153] Triglyceride

[0154] Sodium 0.18 0.18 0.18 0.18 0.18 0.18 methylparaben

[0155] Sodium 0.02 0.02 0.02 0.02 0.02 0.02

[0156] Propylparaben OIL PHASE Cl 8 -21 Alkane 5.0 5.0 5.0 5.0 5.0 5.0

[0157] C21-28 Alkane sTo sTo sTo sTo sTo 5.0

[0158] Caprylic / Capric 5.0 5.0 5.0 5.0 5.0 5.0

[0159] Triglycerides

[0160] These six emulsions were characterized and used for further in vivo tests.

[0161] 3.2. Characterization

[0162] 3.2.1. Rheological analysis

[0163] Rheology analysis is used to characterize and study the changes that occur in the physical structure of the emulsions when there are variations in physical parameters or in the composition of the emulsions. Several rheological tests were used to physically characterize the emulsions described in Table 4, to identify structural changes due to the presence of different concentrations of di-methyl-p-cyclodextrin and fluvoxamine. The tests were performed in a Malvern Kinexus Rheomether (Malvern Instruments, Worcestershire, UK) using a cone plate geometry (truncated cone angle 4° and radius 40 mm) , at 25 °C.

[0164] (i) First, tests related to the viscosity of the samples were performed: table of shear rate, yield stress ramp and ramp up / ramp down tests (Figure 5. A) .

[0165] The table of shear rate rheological test was used to characterize the type of fluid and its behaviour within a given range of shear rate. In this test all the formulations showed similar behaviours, with a gradual decrease in viscosity with increasing shear rates, typical of non-Newtonian fluids with a shear thinning behaviour. A Power Law model was adjusted to the experimental data and the parameters obtained (data not shown) show that emulsions F2, F5 and the placebo are more viscous, with a more stable structural network than the others. The parameters obtained from the fitting also support that all emulsions have a shear thinning behaviour.

[0166] The yield stress ramp test was also performed (Figure 5.B) and the Herschel-Bulkley model was fitted to the experimental data. The conclusions from the parameters obtained (data not shown) agree with those from the previous test, with values typical of non-Newtonian fluids.

[0167] The ramp up / down test studied the behaviour of the emulsions during the increase of the values of shear rate (-up) and afterwards during the decrease of the values of shear rate (-down) (Figure 5.C) . The results show that the emulsions have a hysteretic response, since the change in the behaviour of the fluids depends on the increase / decrease in the shear rate, also indicating that both fluids are thixotropic (as was further confirmed by the thixotropic results) .

[0168] (ii) Second, the samples were submitted to oscillatory tests: strain amplitude sweep and frequency sweep tests.

[0169] The strain amplitude sweep test (y* (%) vs. G' / G' ' (Pa) ) was performed to define the percentage of shear strain corresponding to the linear region of each sample (Fig. 6. A) , which was then used to define the parameters of the frequency sweep test (Fig. 6.B) . The results obtained in this test show G' >G' ' for all emulsions, i.e., the elastic module is superior to the viscous module. The Tan (5) vs. frequency graph (Fig. 6.C) was then defined for the analysis of the liquid or solid properties of each sample. The results vary depending on the frequency, however all Tan (5) values range between 0.1-1 for the established frequency range, meaning that the emulsions have more solid than liquid properties.

[0170] (iii) Finally, the thixotropy test was performed under two different shear rate conditions: the highest shear rate interval (0.1-50 s-1) corresponding to the mimicking of the stress applied to the product when it is spread on the skin, and the shortest shear rate interval (0.1-2 s-1) which mimics the stress applied to the product when it comes out of the storage packaging. The results obtained (not shown) show that all emulsions have a recovery close to or 90%. For all emulsions except the placebo, the shear viscosity values obtained for the two applied ranges were quite similar, suggesting that the emulsions are structurally stable, maintaining their viscosity with the application of different shear rates. Emulsions F2 and F5 had higher viscosity than the other formulations, for both shear ranges. Regarding recovery times, all emulsions except F2, F3 and F5, have higher recovery times for a higher shear rate, which indicates that they took longer to recover their structure after applied to the skin and less time after applying the stress on the packaging where they were stored. However, the opposite was observed for placebo, F3 and F4, and these results are not what would be desired for emulsions. 3.2.2. Droplet size and microscopy analysis

[0171] The droplet size study aimed to obtain more information about the stability of each formulation, by determining the size of the droplets formed by the dispersed phase. The studies were performed in Malvern MasterSizer (Malvern Instruments, Worcestershire, UK) attached to a Hydro S accessory with a water chamber, with a 1750 rpm agitation, at 25 °C.

[0172] The results (Figure 7, Table 5) show that placebo, F4 and F5 emulsions are more homogeneous, with only one defined peak representing the predominant droplet size, with a size range from 1 to 10 pm. Emulsions Fl and F3 have similar profiles, with a wider size range (0.1-50 pm) , meaning lower homogeneity than the previous samples. Emulsion F2 also revealed two peaks, but with a higher volume of smaller droplets (~ 2 pm) than larger droplets (~ 8 pm) .

[0173] Table 5. Droplet size distribution results D (0.1) , D

[0174] (0.5) , D (0.9) and Span for the placebo and fluvoxamine containing formulations (meanlSD, n=3) .

[0175] Droplet size distribution (pm)

[0176] Formulation pan D (0.1) D (0.5) D (0.9)

[0177] Placebo 1.00 1.6210.01 2.621 0.02 4.251 0.004

[0178] Fl 0.04 1.5210.08 6.721 0.38 15.31 1.17

[0179] F2 0.38 1.2910.03 4.0910.86 15.013.72

[0180] F3 0.80 1.7010.05 6.4310.20 13.310.34

[0181] F4 0.00 1.3110.01 2.1110.01 3.4410.08

[0182] F5 0.84 1.3110.004 2.4610.02 5.8310.13 The microscopic characterization of the emulsions was performed using an optical microscope (Nikon Y-TV55 Eclipse Ci) at 4x and 20x amplifications (Figure 8) and the images were analyzed using the ToupView software. The images allowed the study and comparison of the different sizes and distribution of the droplets in the different emulsions.

[0183] The emulsions Fl and F4 visually present a smaller droplet size and a more uniform distribution compared to the other emulsions. The emulsions F3 and F4 also have small droplets, but with a less uniform distribution, with a higher size variation. In the case of the placebo and emulsion F5, a relatively larger droplet size is observed, although the distribution is more uniform for the placebo than for the F5 emulsion.

[0184] 4. In vivo anti-inflammatory and histological studies

[0185] These in vivo studies were similar to the ones described in

[0186] 2.4, but they were aimed to test the anti-inflammatory efficiency of the developed placebo and emulsions (Table 4) in an IMQ-induced psoriasis model in mice. The positive control of inflammation inhibition was the treatment with Dermovate® (containing 0.05 % clobetasol propionate) and the negative control was the treatment with the placebo formulation. The fluvoxamine formulations were 5, 25 and 50 mg / g with 12% of CyD.

[0187] The results for PAST (cumulative) Score are shown in Figure 9. After 5 days of treatment, both emulsions with 25 mg / g and 50 mg / g fluvoxamine showed the lowest cumulative scores, with only the treatment with Dermovate showing a lowest score. Therefore, fluvoxamine topical formulations of the present invention have revealed to be an effective anti-inflammatory in the treatment of psoriasis by administering a dose lower than that orally administered.

[0188] These results were further supported by histology studies as shown in Figure 10.

[0189] Since there are no significant differences in the results obtained with the two highest drug concentrations, the emulsion with 25 mg / g fluvoxamine was chosen to be used as the final formulation .

[0190] 5. In vitro release and permeation studies

[0191] Release and skin permeation / penetration studies were performed using vertical Franz diffusion cells (diffusion area of 1.0 cm2) with 0.45 pm hydrophilic polysulfone membranes (Tuffryn®; Pall Corporation, Port Washington, NY, USA) and fresh pig skin, respectively, after its saturation in receptor phase for 30 minutes. The receptor phase, composed of 0.01 M PBS pH 7.4: ethanol (70:30 % v / v) , was previously studied, to ensure the sink conditions. Infinite doses of fluvoxamine samples were applied on the donor compartment under occlusive conditions and protected from light. The Franz cells were maintained at 32-37 °C with stirring at 300 rpm (Julabo U3 Thermostat and Multimagnetic stirrer SBS®; Labexchange, Paris, France) . Samples from the receptor compartment were collected at pre-defined time points according to the international guidelines, and the same volume was replaced with fresh receptor phase kept at the same temperature. For the permeation study, after 24 hours the skin was carefully cleaned and cut into small pieces. Tetrahydrofuran (1 mL) was added to the skin pieces and stirred for 1 min in a vertical mixer (29,000 rpm) and sonicated for 20 minutes, to obtain the cell lysis. After filtration (0.45 pm) , the supernatant of this assay and the samples of receptor phase were injected on HPLC and the concentration of fluvoxamine was determined. Data (n=6) were expressed as cumulative amount of fluvoxamine released and permeated through the synthetic and biological membranes used, respectively, and the cumulative drug amount retained in skin layers, considering the total amount as the active dose assayed in each formulation. The data obtained (summarized in Figure 11 and Table 6) were computed using DDSolver (Excel-plugin module) and fitted to different kinetic models .

[0192] Table 6. Permeation and retention results.

[0193] Sample Permeated mass Retained mass

[0194] % pg / cm2% pg / cm2

[0195] 25 mg / g

[0196] Fluvoxamine 6.6210.74 50.4412.13 5.9811.58 45.2619.01 emulsion

[0197] 50 mg / g

[0198] Fluvoxamine 0.3110.04 52.4014.60 1.7710.96 301.401161.25 emulsion

[0199] 50 mg / g

[0200] Fluvoxamine 0.5310.08 86.0917.36 5.7711.60 86.0917.36 solution

[0201] In summary, these results demonstrate the efficacy of fluvoxamine in the treatment of psoriasis as a topical formulation, even when applying a lower dose of drug when compared with oral administration. In particular, fluvoxamine as a topical formulation has shown to be effective in an in vivo psoriatic animal model.

Claims

CLAIMS1 . Fluvoxamine for use in the treatment of psoriasis as a topical formulation .2 . Fluvoxamine according to claim 1 characteri zed in that the topical formulation has a drug dose in a range from 25 mg / g to 50 mg / g .3 . Fluvoxamine according to claim 2 characteri zed in that the topical formulation has a drug dose in a range from 20 mg / g to 30 mg / g . 4 . Fluvoxamine according to claim 3 characteri zed in that the topical formulation has a drug dose of 25 mg / g .5 . Fluvoxamine according to claim 1 characteri zed in that the topical formulation is an oil-in-water emulsion .